Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$72.00K$72.00Kderived±0.0% vs Q4 2023 Net Income-$79.73M-$79.73MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$87,471,000N/M Operating Cash Flowderived-$73,332,000N/M Free Cash Flowderived-$73,446,000N/M Margins · derivedOperating margin-121487.5%−22212.5 pt vs Q4 2023
Net margin-110729.2%−17868.1 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 3, 2025 · 62 d after period end